231 related articles for article (PubMed ID: 36088370)
41. Oncogene-induced senescence underlies the mutual exclusive nature of oncogenic KRAS and BRAF.
Cisowski J; Sayin VI; Liu M; Karlsson C; Bergo MO
Oncogene; 2016 Mar; 35(10):1328-33. PubMed ID: 26028035
[TBL] [Abstract][Full Text] [Related]
42. KRAS
Kamata T; Giblett S; Pritchard C
Blood; 2017 Jul; 130(4):514-526. PubMed ID: 28550040
[TBL] [Abstract][Full Text] [Related]
43. Detection of
Olmedillas-López S; Lévano-Linares DC; Alexandre CLA; Vega-Clemente L; Sánchez EL; Villagrasa A; Ruíz-Tovar J; García-Arranz M; García-Olmo D
World J Gastroenterol; 2017 Oct; 23(39):7087-7097. PubMed ID: 29093617
[TBL] [Abstract][Full Text] [Related]
44. STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway.
Wang Z; Yin M; Chu P; Lou M
Aging (Albany NY); 2019 Sep; 11(17):7187-7196. PubMed ID: 31484165
[TBL] [Abstract][Full Text] [Related]
45. Foxm1 transcription factor is required for the initiation of lung tumorigenesis by oncogenic Kras(G12D.).
Wang IC; Ustiyan V; Zhang Y; Cai Y; Kalin TV; Kalinichenko VV
Oncogene; 2014 Nov; 33(46):5391-6. PubMed ID: 24213573
[TBL] [Abstract][Full Text] [Related]
46. MEK1/2 inhibition elicits regression of autochthonous lung tumors induced by KRASG12D or BRAFV600E.
Trejo CL; Juan J; Vicent S; Sweet-Cordero A; McMahon M
Cancer Res; 2012 Jun; 72(12):3048-59. PubMed ID: 22511580
[TBL] [Abstract][Full Text] [Related]
47. Differences in gynecologic tumor development in Amhr2-Cre mice with KRAS
Kun EHS; Tsang YTM; Lin S; Pan S; Medapalli T; Malpica A; Richards JS; Gershenson DM; Wong KK
Sci Rep; 2020 Nov; 10(1):20678. PubMed ID: 33244099
[TBL] [Abstract][Full Text] [Related]
48. Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients.
Falk AT; Yazbeck N; Guibert N; Chamorey E; Paquet A; Ribeyre L; Bence C; Zahaf K; Leroy S; Marquette CH; Cohen C; Mograbi B; Mazières J; Hofman V; Brest P; Hofman P; Ilié M
Lung Cancer; 2018 Jul; 121():70-75. PubMed ID: 29858030
[TBL] [Abstract][Full Text] [Related]
49. Engineered KRAS G12D-Reactive T Cells Show Promise in Pancreatic Cancer.
Cancer Discov; 2022 Aug; 12(8):1833. PubMed ID: 35686834
[TBL] [Abstract][Full Text] [Related]
50. Discovery of Thieno[2,3-d]pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening.
Li L; Liu J; Yang Z; Zhao H; Deng B; Ren Y; Mai R; Huang J; Chen J
Eur J Med Chem; 2022 Apr; 233():114243. PubMed ID: 35276423
[TBL] [Abstract][Full Text] [Related]
51. KRAS(G12D) drives lepidic adenocarcinoma through stem-cell reprogramming.
Juul NH; Yoon JK; Martinez MC; Rishi N; Kazadaeva YI; Morri M; Neff NF; Trope WL; Shrager JB; Sinha R; Desai TJ
Nature; 2023 Jul; 619(7971):860-867. PubMed ID: 37468622
[TBL] [Abstract][Full Text] [Related]
52. High-throughput, single-particle tracking reveals nested membrane domains that dictate KRas
Lee Y; Phelps C; Huang T; Mostofian B; Wu L; Zhang Y; Tao K; Chang YH; Stork PJ; Gray JW; Zuckerman DM; Nan X
Elife; 2019 Nov; 8():. PubMed ID: 31674905
[TBL] [Abstract][Full Text] [Related]
53. [A method of screening highly common neoantigens with immunogenicity in colorectal cancer based on public somatic mutation library].
Qin LL; Li YJ; Liang ZR; Dai L; Li WH; Chen C; Huang YL; Zhang L; Liu SM; Qiu S; Ge YP; Peng WT; Lin XX; Zhang XQ; Dong X; Li B
Yi Chuan; 2020 Jun; 42(6):599-612. PubMed ID: 32694118
[TBL] [Abstract][Full Text] [Related]
54. KRAS K104 modification affects the KRAS
Chen CC; Hsu CY; Lin HY; Zeng HQ; Cheng KH; Wu CW; Tsai EM; Hsieh TH
Sci Rep; 2020 Oct; 10(1):17447. PubMed ID: 33060649
[TBL] [Abstract][Full Text] [Related]
55. TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity.
Liang MC; Ma J; Chen L; Kozlowski P; Qin W; Li D; Goto J; Shimamura T; Hayes DN; Meyerson M; Kwiatkowski DJ; Wong KK
Oncogene; 2010 Mar; 29(11):1588-97. PubMed ID: 19966866
[TBL] [Abstract][Full Text] [Related]
56. T cell receptors employ diverse strategies to target a p53 cancer neoantigen.
Wu D; Gowathaman R; Pierce BG; Mariuzza RA
J Biol Chem; 2022 Mar; 298(3):101684. PubMed ID: 35124005
[TBL] [Abstract][Full Text] [Related]
57. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
58. Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations.
Chen CC; Er TK; Liu YY; Hwang JK; Barrio MJ; Rodrigo M; Garcia-Toro E; Herreros-Villanueva M
PLoS One; 2013; 8(2):e55793. PubMed ID: 23437064
[TBL] [Abstract][Full Text] [Related]
59. KRAS
Zhou ZW; Ambrogio C; Bera AK; Li Q; Li XX; Li L; Son J; Gondi S; Li J; Campbell E; Jin H; Okoro JJ; Xu CX; Janne PA; Westover KD
Cancer Res; 2020 Sep; 80(17):3719-3731. PubMed ID: 32605999
[TBL] [Abstract][Full Text] [Related]
60. Modulation of Mutant
Zhou X; Padanad MS; Evers BM; Smith B; Novaresi N; Suresh S; Richardson JA; Stein E; Zhu J; Hammer RE; O'Donnell KA
Mol Cancer Res; 2019 Feb; 17(2):594-603. PubMed ID: 30409919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
